Vanos

Common Uses

Vanos is a high-potency corticosteroid used to treat the inflammation and itching caused by certain skin conditions. It works by reducing the swelling, redness, and irritation that occur during a skin flare-up.

Conditions Treated

Healthcare providers typically prescribe this medication for:

• Plaque psoriasis: This is a chronic condition where skin cells build up quickly, resulting in thick, silvery scales and itchy, dry, red patches.
• Atopic dermatitis (eczema): A condition that causes the skin to become itchy, red, and inflamed.
• Corticosteroid-responsive dermatoses: A general term for various skin rashes and inflammatory conditions that improve when treated with steroid medications.

Vanos is approved for use in adults and adolescents who are 12 years of age or older.

Mechanism of Action

Vanos contains fluocinonide, a potent corticosteroid. It works by activating natural substances in the skin that reduce swelling and irritation. While the exact way it works is not fully understood, it is known to suppress the immune system's inflammatory response in the area where it is applied.

Anti-inflammatory Effects

The medication helps control the production of chemicals in the body that cause inflammation. By blocking these substances, Vanos reduces the physical symptoms of skin conditions like psoriasis or atopic dermatitis.

Vasoconstriction and Itch Relief

Vanos also works through the following actions:

• Vasoconstriction: It narrows the small blood vessels in the skin, which helps decrease redness and swelling.
• Antipruritic action: It calms the nerves in the skin to provide relief from intense itching.

Common Side Effects

The most common side effects of Vanos typically occur at the site where the cream is applied. These may include:

• Burning, stinging, or itching
• Skin redness or dryness
• Headache
• Cold-like symptoms, such as a sore throat or stuffy nose

Serious Side Effects

Contact a healthcare provider immediately if you experience any of the following serious side effects:

• Severe skin irritation, swelling, or signs of infection
• Thinning of the skin, stretch marks, or spider veins
• Acne-like skin eruptions or inflammation of hair follicles
• Changes in skin color
• Blurred vision or eye pain
• Signs of high blood sugar, such as increased thirst or frequent urination
• Signs of adrenal gland problems, including extreme fatigue, muscle weakness, or weight loss
• Cushing's syndrome, which may involve weight gain in the face and upper back

Systemic Effects and Adrenal Suppression

Because Vanos is a high-potency corticosteroid, it can be absorbed through the skin into the bloodstream. This may lead to reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, which affects how the body produces natural hormones. Symptoms of systemic absorption may include Cushing's syndrome, high blood sugar (hyperglycemia), and glucose in the urine (glucosuria).

The risk of systemic absorption increases if the medication is applied to large surface areas, used for a long time, or used with occlusive dressings such as bandages or plastic wrap. To minimize these risks, treatment is generally limited to two consecutive weeks and no more than 60 grams per week.

Local Skin Reactions

Applying Vanos may cause local skin issues, especially if used on sensitive areas. Potential reactions include:

• Skin atrophy (thinning of the skin)
• Striae (stretch marks)
• Telangiectasias (spider veins)
• Burning, itching, or irritation
• Folliculitis or acne-like breakouts
• Changes in skin color (hypopigmentation)

This medication should typically not be used on the face, groin, or axillae (underarms) because these areas are more prone to skin thinning and absorption.

Vision Problems

Topical corticosteroids used near the eyes may increase the risk of developing cataracts or glaucoma. It is important to avoid getting the cream in the eyes and to report any changes in vision to a healthcare professional.

Pediatric Precautions

Children may be more susceptible to systemic toxicity and HPA axis suppression because they have a larger skin surface area relative to their body weight. Long-term use in children may also interfere with growth and development. Use in pediatric patients should be limited to the least amount necessary for therapeutic results.

Skin Infections

If a skin infection is present or develops during treatment, an appropriate antifungal or antibacterial agent should be used. If the infection does not resolve promptly, the use of Vanos should be discontinued until the infection is properly controlled.

Pregnancy

There are no adequate or well-controlled studies regarding the use of fluocinonide in pregnant women. In animal studies, corticosteroids have been shown to cause birth defects when applied topically or administered systemically. Because human data is limited, this medication should be used during pregnancy only if clearly needed and under the supervision of a healthcare professional.

Breastfeeding

It is not known whether topical application of fluocinonide results in enough systemic absorption for the drug to pass into human breast milk. While corticosteroids taken orally are known to enter breast milk, the risks associated with topical use are less clear.

If you are breastfeeding, consider the following safety measures:

• Consult your healthcare provider to discuss the potential risks to the infant.
• Do not apply the medication to the breast or nipple area to prevent the baby from accidentally ingesting the cream or coming into direct contact with it.
• If application to the chest is necessary, ensure the area is thoroughly cleaned before nursing.

Available Forms

Vanos is available in the following form:

• Topical cream

This medication is intended for external use only. While the active ingredient may be found in other topical preparations like gels or ointments, the Vanos brand is specifically a cream formulation.

FDA Approval and Indications

Vanos (fluocinonide) cream, 0.1%, is approved by the U.S. Food and Drug Administration (FDA) for the relief of inflammatory and pruritic (itchy) manifestations of corticosteroid-responsive dermatoses. It is classified as a super-high potency topical corticosteroid.

Regulatory Status and Age Limits

The FDA has approved Vanos for use in patients 12 years of age and older. Its safety and effectiveness in pediatric patients under the age of 12 have not been established. Because of its high strength, the FDA-approved labeling specifies that treatment should be limited to two consecutive weeks and the total dose should not exceed 60 grams per week.

Safety Communications

There are currently no boxed warnings or Risk Evaluation and Mitigation Strategies (REMS) associated with Vanos. Regulatory labeling includes warnings regarding the potential for systemic absorption, which may lead to reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and high blood sugar (hyperglycemia).

Generic Availability

Vanos is available as a generic medication under the name fluocinonide cream, 0.1%. Generic medications are required by the FDA to have the same active ingredient, strength, and dosage form as the brand-name drug, but they are usually available at a lower price.

Insurance and Pharmacy Factors

The out-of-pocket expense for this medication can be influenced by several factors:

• Insurance Plan: Coverage levels vary between insurance providers. Many plans may require a higher copay for brand-name Vanos or may only cover the generic version.
• Quantity: The size of the tube prescribed, such as 30 grams or 60 grams, will affect the total cost.
• Pharmacy Selection: Prices for both brand and generic versions may differ between local retail pharmacies and mail-order options.